Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 146 recruiting now early-phase tilt #12 of 28,963 conditions

Lung Cancer: early-phase trial registry

146 of 430 indexed Lung Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #12 of 28,963 conditions by registered trial count.

430 US clinical trials · 146 currently recruiting · #12 of 28,963 conditions by registered trial count

Lung Cancer: 430 US clinical trials tracked, 146 recruiting.

Lung Cancer is the subject of 430 registered US clinical trials on ClinicalTrials.gov, 146 of them currently open to new participants. 23 are in Phase 3-4 (later-stage) and 181 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 36 of these trials.

Open enrollment, early-phase tilt

Lung Cancer has 430 registered US clinical trials, 146 of them open to new participants right now, about 34% of the total.

146
recruiting participants now
34%
of trials open to enrollment
23
in Phase 3-4 (later-stage)
36
top sponsor: Memorial Sloan Kettering Cancer Center

Corpus placement: #12 of 28,963 conditions by registered trial count on ClinicalTrials.gov-derived indexes. Registry reference only, not medical advice.

Key findings

What ClinicalTrials.gov does not surface for Lung Cancer on its own pages , computed from the registry mirror as of 2026-07-11. Each line carries its own denominator so it can be quoted as it stands.

  1. Lung Cancer is recruiting below its size-band peers.

    146 of 430 indexed trials (34%) are open to enrollment, against a 37.2% average across 135 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Lung Cancer trials is spread across many organizations.

    Memorial Sloan Kettering Cancer Center accounts for 36 of 430 trials (8.4%). 179 distinct sponsors appear on at least one study for this condition label.

  3. Typical Lung Cancer enrolment sits around 89 participants.

    Median target enrolment is 89 among the 410 trials that report a genuine target (sentinel values excluded). 212 of those (51.7%) plan for fewer than 100 participants.

  4. Lung Cancer research is mostly interventional.

    321 interventional and 109 observational studies make up this index (74.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 185Phase 296Phase 322Phase 41

Open and recent trials

430 total, page 3 of 9

RECRUITING Phase 1 93 participants

A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

BeiGene

NCT06685718

RECRUITING Phase 1 90 participants

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

Clasp Therapeutics

NCT06778863

RECRUITING Phase 2 85 participants

Pulmonary Rehabilitation in Advanced Lung Cancer Survivors

Case Comprehensive Cancer Center

NCT07104630

RECRUITING Phase 2 82 participants

RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial

Masonic Cancer Center, University of Minnesota

NCT04105270

RECRUITING 75 participants

Registry Trial and Needs Assessment of Patients With Young-onset Lung Cancer: Impact of a Dedicated Care Program on Patient Experience and Outcomes

M.D. Anderson Cancer Center

NCT07220096

RECRUITING Phase 2 72 participants

Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury

Massachusetts General Hospital

NCT04485286

RECRUITING Phase 2 70 participants

ChatBot and Activity Monitoring in Patients Undergoing Chemoradiotherapy

Abramson Cancer Center at Penn Medicine

NCT05318027

RECRUITING Phase 2 62 participants

A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain

Memorial Sloan Kettering Cancer Center

NCT05419076

RECRUITING NA 60 participants

Adapting and Testing a Novel Self-Compassion Intervention to Reduce Lung Cancer Stigma

Loyola Marymount University

NCT06191939

RECRUITING NA 60 participants

Virtual Personalized Exercise Program for Lung Cancer Patients

Northwell Health

NCT06540495

RECRUITING Phase 1 60 participants

Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer

Karen Reckamp, MD, MS

NCT05401110

RECRUITING NA 60 participants

Support for Cancer Patients Awaiting News

Hackensack Meridian Health

NCT06199570

RECRUITING Phase 2 60 participants

Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery

Memorial Sloan Kettering Cancer Center

NCT04991025

RECRUITING Phase 1 56 participants

Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements

Joshua Palmer

NCT05987644

RECRUITING Phase 1 52 participants

Safety and Efficacy of OBX-115 in Advanced Solid Tumors

Obsidian Therapeutics

NCT06060613

RECRUITING Phase 2 51 participants

Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial

University of California, Irvine

NCT06580002

RECRUITING NA 50 participants

Dosing Physical Activity Among Older Cancer Survivors Who Experience Chronic Pain: a Micro-randomized Trial

Medical College of Wisconsin

NCT07227077

RECRUITING Phase 2 49 participants

Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)

University of Chicago

NCT05068232

RECRUITING Early Phase 1 48 participants

Testing the Safety of Dapagliflozin Prior to Surgery for the Treatment of Patients With Stage IA Lung Adenocarcinoma

Jonsson Comprehensive Cancer Center

NCT07235280

RECRUITING 48 participants

Longitudinal Evaluation of Microbial and Host Signatures During Immunotherapy for Lung Cancer

NYU Langone Health

NCT04063501

RECRUITING NA 46 participants

Lung Cancer and Aging: Improving Well-being for Older Adults With Lung Cancer

Duke University

NCT06636721

RECRUITING Phase 1 45 participants

Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors

Baylor College of Medicine

NCT03740256

RECRUITING Phase 1 45 participants

Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer

Stanford University

NCT06080061

RECRUITING Phase 2 40 participants

Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®

CivaTech Oncology

NCT03290534

RECRUITING NA 40 participants

Targeted Telerehabilitation Following Curative Intent Therapy of Lung Cancer

VA Office of Research and Development

NCT05179408

RECRUITING Phase 1 40 participants

Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients

M.D. Anderson Cancer Center

NCT04038619

RECRUITING Phase 2 39 participants

REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)

M.D. Anderson Cancer Center

NCT05632809

RECRUITING NA 36 participants

Virtual Agent Feasibility in Oncology Patients (NTT Data)

Duke University

NCT06682013

RECRUITING Phase 1 30 participants

KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer

Christian Hinrichs

NCT05483491

RECRUITING Phase 2 30 participants

Study of Trilaciclib and Lurbinectidin

UNC Lineberger Comprehensive Cancer Center

NCT05578326

RECRUITING 30 participants

MRI and Biomarkers for Lung Nodules Detected During Lung Cancer Screening

Cedars-Sinai Medical Center

NCT05699213

RECRUITING NA 30 participants

Preliminary Efficacy of Different Exercise Training During Immunotherapy in Patients With Lung Cancer: The ENHANCE Trial

Dana-Farber Cancer Institute

NCT06026111

RECRUITING Phase 2 27 participants

A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation

M.D. Anderson Cancer Center

NCT05118854

RECRUITING 25 participants

Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring

Carevive Systems

NCT05974150

RECRUITING 25 participants

Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC

Jun Zhang, MD, PhD

NCT05332925

RECRUITING Early Phase 1 24 participants

Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer

UNC Lineberger Comprehensive Cancer Center

NCT05620342

RECRUITING Phase 2 24 participants

Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial

University of California, Irvine

NCT07447050

RECRUITING NA 20 participants

Study to Evaluate Percussive Ventilation Breathhold to Improve Lung Stereotactic Ablative Radiotherapy

Stanford University

NCT05283564

RECRUITING Phase 1 20 participants

Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer

University of California, Davis

NCT05452005

RECRUITING 20 participants

Full-Field Optical Coherence Tomography (FFOCT) for Evaluation of Bronchoscopic Small Biopsy Specimens

Johns Hopkins University

NCT05171478

RECRUITING NA 20 participants

Accelerated Pulmonary Rehabilitation in the Preoperative Period

University of Vermont

NCT06432972

RECRUITING Phase 1 11 participants

Brodalumab in the Treatment of Immune-Related Adverse Events

Brian Henick, MD

NCT06673329

RECRUITING 10 participants

Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women

Washington University School of Medicine

NCT06904365

RECRUITING NA 10 participants

Avecure Flexible Microwave Ablation Probe For Lung Nodules

Beth Israel Deaconess Medical Center

NCT05281237

RECRUITING Phase 1 5 participants

A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer

Memorial Sloan Kettering Cancer Center

NCT06863233

RECRUITING

DNA Analysis of Blood and Tissue from Patients with Lung Cancer

Massachusetts General Hospital

NCT00471978

ACTIVE NOT RECRUITING NA 42,415 participants

The MyLungHealth Study Protocol: Engaging Patients to Enable Interoperable Lung Cancer Decision Support at Scale

University of Utah

NCT06338592

ACTIVE NOT RECRUITING NA 21,081 participants

Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients

Memorial Sloan Kettering Cancer Center

NCT00579514

ACTIVE NOT RECRUITING 12,000 participants

Screening for High Frequency Malignant Disease

Guardant Health

NCT05117840

ACTIVE NOT RECRUITING 11,935 participants

CASCADE-LUNG: Cancer Screening Assay Using DELFI; A Clinical Validation Study in Lung

Delfi Diagnostics

NCT05306288

← Previous Page 3 of 9 Next →

Phase Distribution

PhaseTrial count
Phase 1 85
Phase 2 96
Phase 3 22
Phase 4 1

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What is open for Lung Cancer right now

146 recruiting of 430 indexed (34% open).

Phase mix: 23 late (III/IV) vs 181 early (I/II) (early-phase heavy).

Top sponsor: Memorial Sloan Kettering Cancer Center (36 trials), 9 others listed. 50 shown below, recruiting first. #12 of 28,963 conditions by registered trial count.

How open-enrollment share is computed

Open share is recruiting_count divided by trial_count for this condition label in the public registry export. Status can change between pulls; treat the figure as a snapshot of research attention, not treatment availability.

Frequently Asked Questions

How many clinical trials are there for Lung Cancer?

PlainTrial tracks 430 US clinical trials for Lung Cancer, of which 146 are currently recruiting participants. Data sourced from ClinicalTrials.gov.

How do I find a recruiting trial for Lung Cancer?

Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.

Is this data current?

Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.

Verify with NIH →

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.